An attractive approach to liver cancer treatment is to bolster the body's own immune defenses. Now an international team involving A*STAR researchers has genetically engineered human T cells to endow them with both specificity against liver cancer cells in patients with Hepatitis B, and the potential for long-term antitumor efficacy.